The Welsh Assembly Government has invested £1m through its SMARTCymru programme to Protherics Plc, a biopharmaceutical company which has its main manufacturing operations in Ceredigion. The grant will be used to support the manufacture of Protherics’ promising anti-sepsis drug CytoFab™, which is being developed in partnership with AstraZeneca. CytoFab™ is a first in class anti-TNF-alpha polyclonal antibody fragment (Fab) product, which is being developed for the treatment of severe sepsis.
A highlight of deal processes underway and involving PE, either on the buy- or sell-side, across Europe
Scarlett Omar Broca and Heiko Geissler join in Paris and Frankfurt, respectively
BCEP II follows a long-hold private equity strategy, with an investment period of 15 years
Combined companies will pursue a buy-and-build strategy, acquiring fitness studio chains